Literature DB >> 8144062

Transient ischemic attacks associated with amfepramone therapy: a case report.

R Crols1, R Dierckx, J Saerens, P P De Deyn.   

Abstract

A 33-year-old man was prescribed amfepramone 75 mg o.i.d. for the treatment of obesity. One week after onset of therapy, he suddenly became agitated and aphasic for several h. A CT scan of the brain was normal. Amfepramone was discontinued. Three days later, there was a second period of agitation and aphasia with a discrete right hemiparesis lasting 12 h. A repeat CT scan and a MRI of the brain were normal. On EEG and brain mapping, alpha-activity was absent over the left hemisphere and a left fronto-temporal delta-focus was found. A Tc-99m HMPAO brain SPECT showed a severe hypoperfusion of the left hemisphere. The next day, the neurological examination was completely normal. Two weeks later, EEG and SPECT had completely normalized. Transient ischemic attacks due to vasospasm were considered to be the most probable clinical diagnosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8144062

Source DB:  PubMed          Journal:  Funct Neurol        ISSN: 0393-5264


  4 in total

Review 1.  Safety of drug therapies used for weight loss and treatment of obesity.

Authors:  Lisa L Ioannides-Demos; Joseph Proietto; Andrew M Tonkin; John J McNeil
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  Technetium-99m HMPAO SPET in acute supratentorial ischaemic infarction, expressing deficits as millilitre of zero perfusion.

Authors:  R A Dierckx; A Dobbeleir; B A Pickut; L Timmermans; I Dierckx; A Vervaet; J Vandevivere; W Deberdt; P P De Deyn
Journal:  Eur J Nucl Med       Date:  1995-05

3.  Mechanisms involved in the vasorelaxant effects produced by the acute application of amfepramone in vitro to rat aortic rings.

Authors:  J S López-Canales; J Lozano-Cuenca; E Muãoz-Islas; J C Aguilar-Carrasco; O A López-Canales; R M López-Mayorga; E F Castillo-Henkel; I Valencia-Hernández; C Castillo-Henkel
Journal:  Braz J Med Biol Res       Date:  2015-03-27       Impact factor: 2.590

Review 4.  Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients.

Authors:  Rosa Camila Lucchetta; Bruno Salgado Riveros; Roberto Pontarolo; Rosana Bento Radominski; Michel Fleith Otuki; Fernando Fernandez-Llimos; Cassyano Januário Correr
Journal:  Clinics (Sao Paulo)       Date:  2017-05       Impact factor: 2.365

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.